Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

The panel outlines combination therapy options for patients with advanced prostate cancer and discusses the potential benefits of intensification of androgen deprivation therapy.

EP: 1.Prostate Cancer Treatment: The Evolving Therapeutic Landscape

EP: 2.The Heterogeneity of Prostate Cancer

EP: 3.The Role of ADT in Localized or Locally Advanced Prostate Cancer

EP: 4.EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

EP: 5.Treatment Considerations in Nonmetastatic CSPC

Now Viewing

EP: 6.Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

EP: 7.Treatment Options in Castration-Resistant Prostate Cancer

EP: 8.The Relationship Between Prostate Cancer and Cardiovascular Disease

EP: 9.Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

EP: 10.ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Related Videos

Related Content

Advertisement

March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.

Related Content

Advertisement

March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.